CLINICAL BENEFIT OF LENALIDOMIDE TREATMENT FOR LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROME WITH DEL(5Q) BEFORE TRANSFUSION DEPENDENCE

被引：0
|
作者：
Oliva, E. [1 ]
Lauseker, M. [2 ]
Spiriti, M. A. Aloe [3 ]
Poloni, A. [4 ]
Cortelezzi, A. [5 ]
Palumbo, G. [6 ]
Balleari, E. [7 ]
Sanpaolo, G. [8 ]
Volpe, A. [9 ]
Ricco, A. [10 ]
Ronco, F. [1 ]
Alati, C. [1 ]
Santacaterina, I. [1 ]
Kuendgen, A. [11 ]
Germing, U. [11 ]
Latagliata, R. [12 ]
机构：
[1] Azienda Osped BMM, Reggio Di Calabria, Italy
[2] Univ Munich, Inst Med Informat Sci Biometry & Epidemiol, Munich, Germany
[3] Univ Roma La Sapienza, Dipartimento Med Clin & Mol, I-00185 Rome, Italy
[4] Univ Politecn Marche, Ancona, Italy
[5] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy
[6] Azienda Osped Univ Policlin Vittorio Emanuele, Catania, Italy
[7] Osped San Martino Genova, Hematol Unit, Genoa, Italy
[8] Osped Casa Sollievo della Sofferenza, Hematol Div, San Giovanni Rotondo, Italy
[9] Azienda Osped San G Moscati, Avellino, Italy
[10] Univ Bari, Bari, Italy
[11] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany
[12] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S1331
引用
收藏
页码：517 / 517
页数：1
相关论文
共 50 条
  • [21] Treatment of myelodysplastic syndromes with del 5q before the lenalidomide era:: The GFM experience.
    Kelaidi, Charikleia
    Park, Sophie
    Brechignac, Sabine
    Mannone, Lionel
    Vey, Norbert
    Dombret, Herve
    Aljassem, Lina
    Starnatoullas, Aspasia
    Ades, Lionel
    Giraudier, Setphane
    de Botton, Stephane
    Mahe, Beatrice
    Lepelley, Pascale
    Picard, Fracoise
    Leroux, Genevieve
    Daniel, Marie-Threrese
    Bouscary, Didier
    Dreyfus, Francois
    Fenaux, Pierre
    BLOOD, 2006, 108 (11) : 757A - 757A
  • [22] IMPACT OF 5Q BREAKPOINTS ON CLINICAL OUTCOMES IN PATIENTS WITH IPSS LOW-/INT-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND ISOLATED DEL(5Q) TREATED WITH LENALIDOMIDE IN THE MDS-004 STUDY
    Gohring, G.
    Giagounidis, A.
    List, A.
    Hellstrom-Lindberg, E.
    Sekeres, M.
    Mufti, G.
    Schlegelbergerl, B.
    Morrill, J.
    Wu, C.
    Skikne, B.
    Fenaux, P.
    HAEMATOLOGICA, 2013, 98 : 80 - 80
  • [23] Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
    Azra Raza
    Naomi Galili
    Deborah Mulford
    Scott E Smith
    Gail L Brown
    David P Steensma
    Roger M Lyons
    Ralph Boccia
    Mikkael A Sekeres
    Guillermo Garcia-Manero
    Ruben A Mesa
    Journal of Hematology & Oncology, 5
  • [24] Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
    Raza, Azra
    Galili, Naomi
    Mulford, Deborah
    Smith, Scott E.
    Brown, Gail L.
    Steensma, David P.
    Lyons, Roger M.
    Boccia, Ralph
    Sekeres, Mikkael A.
    Garcia-Manero, Guillermo
    Mesa, Ruben A.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2012, 5
  • [25] Efficacy to lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q)
    Xiong, Bei
    Liu, XinYue
    Zou, Ping
    Fan, LiHua
    Chen, WanXin
    Li, WeiMing
    Liu, Lin
    LEUKEMIA RESEARCH, 2010, 34 (07) : E169 - E172
  • [26] Activity of Lenalidomide in a Phase II Single Institution Study in Non-Del(5q) Transfusion Dependent, Patients with Low and Intermediate-1 Risklower-Risk, Non-Del(5q) Myelodysplastic Syndromes (MDS))): Results From a Single-Institution Phase II Study
    Raza, Azra
    Falkenstern, John
    Yeh, Fiona
    Castagna, Ginevra
    De Los Reyes, Antonietta
    Galili, Naomi
    BLOOD, 2012, 120 (21)
  • [27] Health and economic impact of the discontinuation of lenalidomide treatment in patients with myelodysplastic syndrome associated with del(5q)
    Alarcon-Payer, C.
    Salazar Bravo, M.
    Jimenez Morales, A.
    Garcia Fumero, R.
    Jurado Chacon, M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 380 - 380
  • [28] Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy
    Oliva, Esther N.
    Latagliata, Roberto
    Lagana, Carmelo
    Breccia, Massimo
    Galimberti, Sara
    Morabito, Fortunato
    Poloni, Antonella
    Balleari, Enrico
    Cortelezzi, Agostino
    Palumbo, Giuseppe
    Sanpaolo, Grazia
    Volpe, Antonio
    Specchia, Giorgina
    Finelli, Carlo
    D'Errigo, Maria Grazia
    Roda, Filippo
    Alati, Caterina
    Alimena, Giuliana
    Nobile, Francesco
    Spiriti, Maria A. Aloe
    LEUKEMIA & LYMPHOMA, 2013, 54 (11) : 2458 - 2465
  • [29] CLINICAL FACTORS PREDISPOSING TO ACHIEVEMENT OF RBC TRANSFUSION INDEPENDENCEIN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES) WITHOUT DEL(5q) IN MDS-005 STUDY
    Santini, V.
    Li, J. Shiansong
    Swern, A. S.
    Almeida, A.
    Giagounidis, A.
    Fu, T.
    Sanna, A.
    Hoenekopp, A.
    Beach, C. L.
    Skikne, B.
    Fenaux, P.
    HAEMATOLOGICA, 2015, 100 : 3 - 4
  • [30] Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion-The GFM experience
    Le Bras, Fabien
    Sebert, Marie
    Kelaidi, Charikleia
    Lamy, Thierry
    Dreyfus, Francois
    Delaunay, Jacques
    Banos, Anne
    Blanc, Michel
    Vey, Norbert
    Schmidt, Aline
    Visanica, Sorin
    Eclache, Virginie
    Turlure, Pascal
    Beyne-Rauzy, Odile
    Guerci, Agnes
    Delmer, Alain
    de Botton, Stephane
    Rea, Delphine
    Fenaux, Pierre
    Ades, Lionel
    LEUKEMIA RESEARCH, 2011, 35 (11) : 1444 - 1448
12345